Bech-Bruun advises BioAlliance Pharma
BioAlliance Pharma and Topotarget enter into a merger agreement to create a leading orphan oncology company. Bech-Bruun acted as legal counsel to BioAlliance Pharma during the entire transaction.
BioAlliance Pharma and Topotarget have announced their intention to merge to create a leading orphan oncology company with a highly complementary pipeline of late-stage products addressing significant unmet medical needs. The merger agreement has been unanimously approved by the boards of directors of both companies.
Bech-Bruun acted as legal counsel to BioAlliance Pharma during the entire transaction, which continued for more than a year. To our knowledge, the transaction is, as far as is known, the first cross-border merger between companies from different groups to be completed under the provisions thereon laid down in the Danish Companies Act (selskabsloven).
The merger is expected to be approved at extraordinary general meetings in Topotarget and BioAlliance Pharma on 27 June, 2014 and 30 June, 2014, respectively.
About the businesses
BioAlliance Pharma SA designs, develops and markets innovative drugs within orphan oncology diseases. Topotarget A/S is a Danish biopharmaceutical company, currently focusing on the company’s primary product, belinostat, which has potential for being explored into rare cancer indications within hematology and solid tumors.
See the announcement to NASDAQ OMX Copenhagen.